On 16 January 2020, the Australian Securities Exchange (ASX) jumped to its highest level ever after surpassing the 7,000-point milestone for the first time in its entire history. S&P/ASX 200 Consumer Staples (Sector) ended the session at 12,946.7, reflecting a rise of 143.2 points or 1.11%. S&P/ASX 200 Financials (Sector) experienced an increase of 1.06% and stood at 6,233.0. At the close of the trading session, All Ordinaries settled at 7158.6, indicating a rise of 45.1 points.
Moving towards the performance of some companies, which ended the session in green, including Challenger Limited (ASX:CGF), which closed at A$8.800 per share, up by 5.642% from its previous closing price. PolyNovo Limited (ASX:PNV) experienced an increase of 5.263% and settled at A$2.400 per share.
Looking at NZX Main Board, TRS Investments Ltd (NZX: TRS) closed at NZ$0.003 per share with a surge of 50.00%. Green Cross Health Limited (NZX: GXH) settled at NZ$1.340, reflecting a rise of 7.20% on an intraday basis. Moving to the losers, Gentrack Group Limited (NZX: GTK) declined by 8.65% and closed at NZ$2.640. Evolve Education Group Limited (NZX: EVO) ended the session at a closing price of NZ$0.170, reflecting a fall of 4.49%.
Recently, we penciled an article on Great Western Exploration Limited (ASX:GTE) and readers are to have a glance on the important information covered. To view, please click here.
Challenger Limited Experiences Rise of 5.642% on Australian Stock Exchange
Challenger Limited (ASX:CGF) became an initial substantial holder in Pendal Group Ltd on 20th December 2019 with a voting power of 5.08%.
On the financial front, the total Life sales witnessed a fall of 18% in FY19 and stood at $4.6 billion, primarily because of lower sales of Australian dollar denominated annuities in Japan. Additionally, the company’s expanded strategic relationship with MS&AD, which was announced in March 2019, boosted its offering with the inclusion of US dollar annuity products.
During FY19, the company brought new products to the market, added new boutique managers, and rolled out the ActiveX Series, Fidante’s actively managed Exchange Traded Funds in its fund management business
PolyNovo Limited Closes the Session in Green
For PolyNovo Limited (ASX:PNV), December 2019 became the first ever two-million-dollar month, against revenue of $890k December 2018 from NovoSorb BTM sales (unaudited). BTM stands for Biodegradable Temporising Matrix and provides the best opportunity for dermal repair.
Through another company release, PNV notified the market with recent tragedy of White Island in New Zealand and delivered NovoSorb BTM to 3 hospitals in New Zealand along with 2 Australian Hospitals. Also, NovoSorb BTM has been awarded a certificate of conformance or CE Mark approval for sale across the UK/Ireland and the European Union.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.